nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.08.2012 | Epidemiology

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008

verfasst von: Jennifer A. Schlichting, Amr S. Soliman, Catherine Schairer, David Schottenfeld, Sofia D. Merajver

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Although it has been previously reported that patients with inflammatory breast cancer (IBC) experience worse survival than patients with other breast cancer (BC) types, the socioeconomic and ethnic factors leading to this survival difference are not fully understood. The association between county-level percent of persons below the poverty level and BC-specific (BCS) survival for cases diagnosed from 1990 to 2008 in the Surveillance, Epidemiology, and End Results (SEER) database linked to census derived county attributes was examined. A sub-analysis of cases from 2000 to 2008 also examined BCS survival by an index combining percent below poverty and less than high school graduates as well as metropolitan versus non-metropolitan county of residence. The Kaplan–Meier estimator was used to construct survival curves by stage, inflammatory status, and county-level socioeconomic position (SEP). Stage and inflammatory status stratified proportional hazards models, adjusted for age, race/ethnicity, tumor and treatment characteristics were used to determine the hazard of BCS death by county-level SEP. Kaplan–Meier survival curves indicated IBC has worse survival than stage matched non-IBC, (stage III IBC median survival = 4.75 years vs. non-IBC = 13.4 years, p < 0.0001). Residing in a lower SEP, non-metro county significantly worsens BCS survival for non-IBC in multivariate proportional hazards models. African American cases appear to have worse survival than non-Hispanic Whites regardless of inflammatory status, stage, county-level SEP, tumor, or treatment characteristics. This is the first study to examine IBC survival by SEP in a nation-wide population-based tumor registry. As this analysis found generally poorer survival for IBC, regardless of SEP or race/ethnicity, it is important that interventions that help educate women on IBC symptoms target women in various SEP and race/ethnicity groups.

Anderson WF, Chen BE, Jatoi I et al (2006) Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121–126PubMedCrossRef

Anderson WF, Schairer C, Chen BE et al (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed

Chang S, Alderfer JR, Asmar L et al (2000) Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64:157–163PubMedCrossRef

Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975PubMedCrossRef

Chang S, Parker SL, Pham T et al (1998) Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975–1992. Cancer 82:2366–2372PubMedCrossRef

Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21:2254–2259PubMedCrossRef

Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117:1819–1826PubMedCrossRef

Merajver SD, Weber BL, Cody R et al (1997) Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 15:2873–2881PubMed

Gonzalez-Angulo AM, Hennessy BT, Broglio K et al (2007) Trends for inflammatory breast cancer: is survival improving? Oncologist 12:904–912PubMedCrossRef

10.

Levine PH, Steinhorn SC, Ries LG et al (1985) Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 74:291–297PubMed

11.

Yang R, Cheung MC, Hurley J et al (2009) A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat 117:631–641PubMedCrossRef

12.

Dawood S, Ueno NT, Valero V et al (2012) Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870–875PubMedCrossRef

13.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2009 Sub (1973–2007 varying)-Linked To County Attributes-Total U.S., 1969–2007 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission

14.

Surveillance Epidemiology and End Results Program (2011) Overview of the SEER Program. http://seer.cancer.gov/about/overview.html. Accessed 02 Apr 2012

15.

American Joint Committee on Cancer (2010) Breast. In: Edge SB, Byrd DR, Compton CR et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York

16.

Schairer C, Brown LM, Mai PL (2011) Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat 129(1):117–124PubMedCrossRef

17.

Schlichting JA, Soliman AS, Schairer C et al (2012) Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000–2007. Cancer Epidemiol Biomarkers Prev 21:155–165PubMedCrossRef

18.

Surveillance Epidemiology and End Results Program (2011) SEER research record description: cases diagnosed in 1973–2008. http://seer.cancer.gov/manuals/TextData.FileDescription.pdf. Accessed 02 Apr 2012

19.

SEER Program Quality Control Section (2009) ICD-O-3 SEER site/histology validation list. http://seer.cancer.gov/icd-o-3/sitetype.icdo3.d20091204.pdf. Accessed 02 Apr 2012

20.

Johnson CH (ed) (2004) SEER program coding and staging manual, revision 1. NIH Publication Number 04-5581. National Cancer Institute, Bethesda, MD

21.

Fritz A, Ries L; Cancer Statistics Branch, Surveillance Program, Division of Cancer Control and Population Sciences, National Cancer Institute (eds) (1998) Breast: C50.0-C50.6, C50.8-C50.9. In: SEER extent of disease 1988: codes and coding instructions, 3rd edn. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD

22.

Johnson CH, Adamo M (eds) SEER program coding and staging manual 2007. NIH Publication Number 07-5581, 2008 revision. National Cancer Institute, Bethesda, MD

23.

Surveillance, Epidemiology, and End Results Program (2009) County attributes. http://seer.cancer.gov/seerstat/variables/countyattribs/index.html. Accessed 02 Apr 2012

24.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat database: county attributes—total U.S., 1969–2007 counties (www.seer.cancer.gov/seerstat/variables/countyattribs). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch

25.

Yu XQ (2009) Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer 9:364PubMedCrossRef

26.

Crowell RE, Goetz T, Wiggins C et al (2007) Regional disparities in treatment and survival of early stage non-small cell lung cancer. Ethn Dis 17:358–364PubMed

27.

Reid-Arndt SA, Cox CR (2010) Does rurality affect quality of life following treatment for breast cancer? J Rural Health 26:402–405PubMedCrossRef

28.

Klein J, Ji M, Rea NK et al (2011) Differences in male breast cancer stage, tumor size at diagnosis, and survival rate between metropolitan and nonmetropolitan regions. Am J Mens Health 5(5):430–437PubMedCrossRef

29.

Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515–523PubMedCrossRef

30.

Dushkin H, Cristofanilli M (2011) Inflammatory breast cancer. J Natl Compr Canc Netw 9:233–240PubMed

31.

Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60:351–375PubMedCrossRef

32.

Kotwall CA, Covington DL, Rutledge R et al (1996) Patient, hospital, and surgeon factors associated with breast conservation surgery. A statewide analysis in North Carolina. Ann Surg 224:419–426PubMedCrossRef

33.

Dolan JT, Granchi TS (1998) Low rate of breast conservation surgery in large urban hospital serving the medically indigent. Am J Surg 176:520–524PubMedCrossRef

34.

Roetzheim RG, Gonzalez EC, Ferrante JM et al (2000) Effects of health insurance and race on breast carcinoma treatments and outcomes. Cancer 89:2202–2213PubMedCrossRef

35.

Wu XC, Lund MJ, Kimmick GG et al (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30:142–150PubMedCrossRef

36.

Brouwers B, Paridaens R, Lobelle JP et al (2008) Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer. Tumour Biol 29:211–216PubMedCrossRef

37.

Chang S, Buzdar AU, Hursting SD (1998) Inflammatory breast cancer and body mass index. J Clin Oncol 16:3731–3735PubMed

38.

Dawood S, Broglio K, Gong Y et al (2008) Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 112:1905–1911PubMedCrossRef

39.

Houchens NW, Merajver SD (2008) Molecular determinants of the inflammatory breast cancer phenotype. Oncology 22:1556–1561PubMed

40.

Kleer CG, Zhang Y, Pan Q et al (2004) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 6:R110–R115CrossRef

41.

Le MG, Arriagada R, Bahi J et al (2006) Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? Breast 15:355–362PubMedCrossRef

42.

Lo AC, Georgopoulos A, Kleer CG et al (2009) Analysis of RhoC expression and lymphovascular emboli in inflammatory vs. non-inflammatory breast cancers in Egyptian patients. Breast 18:55–59PubMedCrossRef

43.

Turpin E, Bieche I, Bertheau P et al (2002) Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21:7593–7597PubMedCrossRef

44.

Newman LA (2005) Breast cancer in African-American women. Oncologist 10:1–14PubMedCrossRef

45.

Martinez SR, Tseng WH, Canter RJ et al (2012) Do radiation use disparities influence survival in patients with advanced breast cancer? Cancer 118:196–204PubMedCrossRef

46.

Newman LA, Mason J, Cote D et al (2002) African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer 94:2844–2854PubMedCrossRef

47.

Freeman HP, Wasfie TJ (1989) Cancer of the breast in poor black women. Cancer 63:2562–2569PubMedCrossRef

48.

Liberman L, Freeman HP, Chandra S et al (2002) Carcinoma detection at the breast examination center of Harlem. Cancer 95:8–14PubMedCrossRef

49.

Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490–496PubMedCrossRef

50.

Krieger N, Chen JT, Waterman PD et al (2002) Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. Am J Epidemiol 156:471–482PubMedCrossRef

51.

Singh GK, Miller BA, Hankey BF, Edwards BK (2003) Area socioeconomic variations in U.S. cancer incidence, mortality, stage, treatment, and survival, 1975–1999. NCI cancer surveillance monograph series, number 4. NIH Publication No. 03-5417. National Cancer Institute, Bethesda, MD

52.

Ward E, Jemal A, Cokkinides V et al (2004) Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78–93PubMedCrossRef

53.

Bishaw A (2005) Areas with concentrated poverty: 1999. Census 2000 special reports CENSR-16. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, Washington, DC. http://www.census.gov/prod/2005pubs/censr-16.pdf. Accessed 02 Apr 2012

54.

Howlader N, Noone A, Krapcho M et al (2011) SEER cancer statistics review, 1975–2008. http://seer.cancer.gov/csr/1975_2008/. Accessed 02 Apr 2012. Based on November 2010 SEER data submission, posted to SEER website, 2011

55.

Elledge RM, Clark GM, Chamness GC et al (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86:705–712PubMedCrossRef

56.

Kovi J, Mohla S, Norris HJ et al (1989) Breast lesions in black women. Pathol Annu 24(Pt 1):199–218PubMed

57.

Mohla S, Enterline JP, Sampson CC et al (1982) A predominance of poorly differentiated tumors among black breast cancer patients: management and screening implications. Prog Clin Biol Res 83:249–258PubMed

58.

Mohla S, Sampson CC, Khan T et al (1982) Estrogen and progesterone receptors in breast cancer in Black Americans: correlation of receptor data with tumor differentiation. Cancer 50:552–559PubMedCrossRef

59.

Chen VW, Correa P, Kurman RJ et al (1994) Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomark Prev 3:127–135

60.

Newman LA, Alfonso AE (1997) Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann Surg Oncol 4:655–662PubMedCrossRef

61.

Swanson GM, Lin CS (1994) Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 16:69–77PubMed

62.

Newman LA, Bunner S, Carolin K et al (2002) Ethnicity related differences in the survival of young breast carcinoma patients. Cancer 95:21–27PubMedCrossRef

63.

National Cancer Institute (2005) SEER: Surveillance, Epidemiology, and End Results Program brochure. NIH Publication No. 05-4772. http://seer.cancer.gov/about/SEER_brochure.pdf. Accessed 02 Apr 2012

64.

Dawood S, Cristofanilli M (2011) Inflammatory breast cancer: what progress have we made? Oncology (Williston Park) 25(264–70):273

65.

Dawood S (2010) Biology and management of inflammatory breast cancer. Expert Rev Anticancer Ther 10:209–220PubMedCrossRef

66.

Wingo PA, Jamison PM, Young JL et al (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15:321–328PubMedCrossRef

67.

Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116:2745–2747PubMedCrossRef

68.

Woodward WA, Cristofanilli M (2009) Inflammatory breast cancer. Semin Radiat Oncol 19:256–265PubMedCrossRef

69.

Yu JB, Gross CP, Wilson LD et al (2009) NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park) 23:288–295

70.

Morgenstern H (2008) Ecologic studies. In: Rothman KJ, Greenland S, Lash TL (eds) Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, PA

71.

Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82:703–710PubMedCrossRef

72.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor marker prognostic studies (REMARK). J Clin Oncol 100(23):9067–9072

Titel: Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008
verfasst von: Jennifer A. Schlichting
Amr S. Soliman
Catherine Schairer
David Schottenfeld
Sofia D. Merajver
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2133-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer

Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance

Germline copy number variants are not associated with globally acquired copy number changes in familial breast tumours

Letter in response: the value of mammography screening

Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie